|
1
|
Rhead B, Bäärnhielm M, Gianfrancesco M,
Mok A, Shao X, Quach H, Shen L, Schaefer C, Link J, Gyllenberg A,
et al: Mendelian randomization shows a causal effect of low vitamin
D on multiple sclerosis risk. Neurol Genet. 2:e972016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sahraian MA, Sahebkar M, Dehghani R,
Derakhshan-Jazari M, Kazami-Moghaddam V and Kouchaki E: Multiple
sclerosis-A disease on a dramatically rising trend in Iran: Review
of possible reasons. Iran J Neurol. 16:34–40. 2017.PubMed/NCBI
|
|
3
|
Dargahi N, Katsara M, Tselios T,
Androutsou ME, de Courten M, Matsoukas J and Apostolopoulos V:
Multiple sclerosis: Immunopathology and treatment update. Brain
Sci. 7:E782017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harbo HF, Gold R and Tintoré M: Sex and
gender issues in multiple sclerosis. Ther Adv Neurol Disorder.
6:237–248. 2013. View Article : Google Scholar
|
|
5
|
Johnson KM, Zhou H, Lin F, Ko JJ and
Herrera V: Real-world adherence and persistence to oral
disease-modifying therapies in multiple sclerosis patients over 1
year. J Manag Care Spec Pharm. 23:844–852. 2017.PubMed/NCBI
|
|
6
|
Mescheriakova JY, Broer L, Wahedi S,
Uitterlinden AG, van Duijn CM and Hintzen RQ: Burden of genetic
risk variants in multiple sclerosis families in the Netherlands.
Mult Scler J Exp Transl Clin. 2:20552173166487212016.PubMed/NCBI
|
|
7
|
Fernando MM, Stevens CR, Walsh EC, De
Jager PL, Goyette P, Plenge RM, Vyse TJ and Rioux JD: Defining the
role of the MHC in autoimmunity: A review and pooled analysis. PLoS
Genet. 4:e10000242008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moutsianas L, Jostins L, Beecham AH,
Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson
L, Anderson CA, et al; International IBD Genetics Consortium
(IIBDGC), . Class II HLA interactions modulate genetic risk for
multiple sclerosis. Nat Genet. 47:1107–1113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parnell GP and Booth DR: The multiple
sclerosis (MS) genetic risk factors indicate both acquired and
innate immune cell subsets contribute to MS pathogenesis and
identify novel therapeutic opportunities. Front Immunol. 8:4252017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Polman CH, Reingold SC, Banwell B, Clanet
M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M,
Kappos L, et al: Diagnostic criteria for multiple sclerosis: 2010
revisions to the McDonald criteria. Ann Neurol. 69:292–302. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Institute of Medicine (US) Committee on
Multiple Sclerosis: Current Status and Strategies for the Future.
Multiple Sclerosis. Joy JE and Johnston RB Jr: National Academies
Press; Washington, DC: 2001
|
|
12
|
Moosazadeh M, Esmaeili R, Mehdi Nasehi M,
Abedi G, Afshari M, Farshidi F and Kheradmand M: Prevalence of
familial multiple sclerosis in Iran: A systematic review and
meta-analysis. Iran J Neurol. 16:90–95. 2017.PubMed/NCBI
|
|
13
|
Deleu D, Mir D, Al Tabouki A, Mesraoua R,
Mesraoua B, Akhtar N, Al Hail H, D'souza A, Melikyan G, Imam YZ, et
al: Prevalence, demographics and clinical characteristics of
multiple sclerosis in Qatar. Mult Scler. 19:816–819. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Link J, Lundkvist Ryner M, Fink K,
Hermanrud C, Lima I, Brynedal B, Kockum I, Hillert J and
Fogdell-Hahn A: Human leukocyte antigen genes and interferon beta
preparations influence risk of developing neutralizing anti-drug
antibodies in multiple sclerosis. PLoS One. 9:e904792014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hebbring SJ, Schrodi SJ, Ye Z, Zhou Z,
Page D and Brilliant MH: A PheWAS approach in studying
HLA-DRB1*1501. Genes Immun. 14:187–191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Anagnostouli MC, Acquaviva T, Artemiadis
AK, Rentzos M, Karandreas N, Davaki P and Stamboulis E: HLA-DRB1*
alleles genotyping in chronic inflammatory demyelinating
polyneuropathy in Greek patients. J Peripher Nerv Syst. 19:187–189.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cocco E, Sardu C, Pieroni E, Valentini M,
Murru R, Costa G, Tranquilli S, Frau J, Coghe G, Carboni N, et al:
HLA-DRB1-DQB1 haplotypes confer susceptibility and resistance to
multiple sclerosis in Sardinia. PLoS One. 7:e339722012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Healy BC, Liguori M, Tran D, Chitnis T,
Glanz B, Wolfish C, Gauthier S, Buckle G, Houtchens M, Stazzone L,
et al: HLA B*44: Protective effects in MS susceptibility and MRI
outcome measures. Neurology. 75:634–640. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alcina A, Abad-Grau MM, Fedetz M,
Izquierdo G, Lucas M, Fernández O, Ndagire D, Catalá-Rabasa A, Ruiz
A, Gayán J, et al: Multiple sclerosis risk variant HLA-DRB1*1501
associates with high expression of DRB1 gene in different human
populations. PLoS One. 7:e298192012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Patsopoulos NA, Barcellos LF, Hintzen RQ,
Schaefer C, van Duijn CM, Noble JA, Raj T, Gourraud PA, Stranger
BE, Oksenberg J, et al; IMSGC; ANZgene, . Fine-mapping the genetic
association of the major histocompatibility complex in multiple
sclerosis: HLA and non-HLA effects. PLoS Genet. 9:e10039262013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Al-Shammri S, Nelson RF, Al-Muzairi I and
Akanji AO: HLA determinants of susceptibility to multiple sclerosis
in an Arabian Gulf population. Mult Scler. 10:381–386. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chao MJ, Barnardo MC, Lincoln MR,
Ramagopalan SV, Herrera BM, Dyment DA, Montpetit A, Sadovnick AD,
Knight JC and Ebers GC: HLA class I alleles tag HLA-DRB1*1501
haplotypes for differential risk in multiple sclerosis
susceptibility. Proc Natl Acad Sci USA. 105:13069–13074. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Link J, Kockum I, Lorentzen AR, Lie BA,
Celius EG, Westerlind H, Schaffer M, Alfredsson L, Olsson T,
Brynedal B, et al: Importance of human leukocyte antigen (HLA)
class I and II alleles on the risk of multiple sclerosis. PLoS One.
7:e367792012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kalanie H, Kamgooyan M, Sadeghian H and
Kalanie AR: Histocompatibility antigen (HLA) associations with
multiple sclerosis in Iran. Mult Scler. 6:317–319. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Smagina IV, El'chaninova SA, Zolovkina AG,
Ignatova IuN and Kudriavtseva EA: Genetic risk factors for multiple
sclerosis in the population of Altay. Zh Nevrol Psikhiatr Im S S
Korsakova. 111:42–45. 2011.(In Russian). PubMed/NCBI
|
|
26
|
Saleem MA, Mukhelif HF, Moussawi KM and
Al-Khafaji JT: Human leukocyte antigen typing in Iraqi multiple
sclerosis patients. Neurosciences (Riyadh). 12:127–132.
2007.PubMed/NCBI
|
|
27
|
Gough SC and Simmonds MJ: The HLA region
and autoimmune disease: Associations and mechanisms of action. Curr
Genomics. 8:453–465. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jilek S, Schluep M, Harari A, Canales M,
Lysandropoulos A, Zekeridou A, Pantaleo G and Du Pasquier RA:
HLA-B7-restricted EBV-specific CD8+ T cells are
dysregulated in multiple sclerosis. J Immunol. 188:4671–4680. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Amirzargar AA, Tabasi A, Khosravi F,
Kheradvar A, Rezaei N, Naroueynejad M, Ansaripour B, Moradi B and
Nikbin B: Optic neuritis, multiple sclerosis and human leukocyte
antigen: Results of a 4-year follow-up study. Eur J Neurol.
12:25–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hillert J: Human leukocyte antigen studies
in multiple sclerosis. Ann Neurol. 36 Suppl 1:S15–S17. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Uría DF: HLA and multiple sclerosis.
Studies of a spanish population. Rev Neurol. 31:1066–1070.
2000.PubMed/NCBI
|
|
32
|
Perini P, Tagliaferri C, Belloni M, Biasi
G and Gallo P: The HLA-DR13 haplotype is associated with ‘benign’
multiple sclerosis in northeast Italy. Neurology. 57:158–159. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Barcellos LF, Oksenberg JR, Begovich AB,
Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D,
Lincoln RR, Bucher P, et al; Multiple Sclerosis Genetics Group, .
HLA-DR2 dose effect on susceptibility to multiple sclerosis and
influence on disease course. Am J Hum Genet. 72:710–716. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vasconcelos CC, Fernández O, Leyva L,
Thuler LC and Alvarenga RM: Does the DRB1*1501 allele confer more
severe and faster progression in primary progressive multiple
sclerosis patients? HLA in primary progressive multiple sclerosis.
J Neuroimmunol. 214:101–103. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schmidt H, Williamson D and Ashley-Koch A:
HLA-DR15 haplotype and multiple sclerosis: A HuGE review. Am J
Epidemiol. 165:1097–1109. 2007. View Article : Google Scholar : PubMed/NCBI
|
